ECSP21079184A - Anticuerpos contra amiloide-beta con piroglutamato y usos de estos - Google Patents

Anticuerpos contra amiloide-beta con piroglutamato y usos de estos

Info

Publication number
ECSP21079184A
ECSP21079184A ECSENADI202179184A ECDI202179184A ECSP21079184A EC SP21079184 A ECSP21079184 A EC SP21079184A EC SENADI202179184 A ECSENADI202179184 A EC SENADI202179184A EC DI202179184 A ECDI202179184 A EC DI202179184A EC SP21079184 A ECSP21079184 A EC SP21079184A
Authority
EC
Ecuador
Prior art keywords
amyloid
pyroglutamate
antigen
binding fragments
beta antibodies
Prior art date
Application number
ECSENADI202179184A
Other languages
English (en)
Inventor
Marc Mercken
Wilson Edwards
Jinquan Luo
Broeck Bianca Van
Chichi Huang
Porte Sherry La
Sanjaya Singh
Rajkumar Ganesan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP21079184A publication Critical patent/ECSP21079184A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona anticuerpos o fragmentos de unión al antígeno de estos que se unen a Aβ 3pE y métodos para elaborar y usar los anticuerpos o fragmentos de unión al antígeno de estos, que incluyen el uso para formulaciones, administración y kits. El anticuerpo y fragmentos de unión al antígeno de este y los métodos descritos son útiles para el diagnóstico, pronóstico y tratamiento de la enfermedad de Alzheimer u otras enfermedades relacionadas con el amiloide β.
ECSENADI202179184A 2019-03-26 2021-10-26 Anticuerpos contra amiloide-beta con piroglutamato y usos de estos ECSP21079184A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962823785P 2019-03-26 2019-03-26

Publications (1)

Publication Number Publication Date
ECSP21079184A true ECSP21079184A (es) 2021-11-30

Family

ID=70008544

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202179184A ECSP21079184A (es) 2019-03-26 2021-10-26 Anticuerpos contra amiloide-beta con piroglutamato y usos de estos

Country Status (22)

Country Link
US (4) US11236155B2 (es)
EP (1) EP3946603A1 (es)
JP (2) JP7617848B2 (es)
KR (1) KR20210143858A (es)
CN (2) CN120468431A (es)
AU (1) AU2020245031A1 (es)
BR (1) BR112021019107A2 (es)
CA (1) CA3134785A1 (es)
CL (2) CL2021002473A1 (es)
CO (1) CO2021014028A2 (es)
CR (1) CR20210492A (es)
DO (1) DOP2021000199A (es)
EA (1) EA202192606A1 (es)
EC (1) ECSP21079184A (es)
IL (1) IL286634A (es)
JO (1) JOP20210265A1 (es)
MA (1) MA55491A (es)
MX (1) MX2021011715A (es)
PE (1) PE20212266A1 (es)
PH (1) PH12021552334A1 (es)
SG (1) SG11202110504XA (es)
WO (1) WO2020193644A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
WO2020193644A1 (en) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング，インコーポレイテッド ガレクチン－３を遮断することにより炎症性疾患を処置する方法
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
TW202334200A (zh) * 2021-10-28 2023-09-01 美商艾伯維有限公司 抗澱粉樣蛋白β抗體及其使用方法
AU2023232448A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
AU2023230027A1 (en) 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
AU2023232447A1 (en) * 2022-03-11 2024-10-24 Janssen Pharmaceutica Nv Multispecific antibodies and uses thereof
IL321331A (en) 2022-12-22 2025-08-01 Bioarctic Ab Antibody that binds to ABETAPE3
US20250388664A1 (en) 2024-06-20 2025-12-25 Bioarctic Ab Bispecific binding molecule
CN118459582B (zh) * 2024-07-11 2024-11-15 苏州近岸蛋白质科技股份有限公司 一种抗焦谷氨酸修饰的β淀粉样蛋白抗体及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US20110182809A1 (en) 2008-07-09 2011-07-28 University Of Zurich Method of Promoting Neurogenesis
NZ590563A (en) 2008-07-21 2012-06-29 Probiodrug Ag Diagnostic antibody assay
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
CA2787657A1 (en) * 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
LT3339323T (lt) 2010-08-12 2020-02-10 Eli Lilly And Company Amiloido beta peptido antikūnai prieš n3glu ir jų panaudojimas
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2015191825A1 (en) 2014-06-13 2015-12-17 Biogen Ma Inc. Methods for the detection and measurement of amyloid beta in biological samples
PT3177642T (pt) * 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
JP7002811B2 (ja) * 2015-07-16 2022-03-04 ビボリョン セラピューティクス エヌブイ 抗ピログルタミン酸化アミロイドβヒト化抗体
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TW201740954A (zh) 2016-03-16 2017-12-01 美國禮來大藥廠 組合療法
EP3249388A1 (en) 2016-05-23 2017-11-29 Raman Health Technologies, S.L Method for diagnosing alzheimer´s disease
MX2018015022A (es) 2016-06-07 2019-08-14 Biogen Int Neuroscience Gmbh Métodos para el tratamiento de la enfermedad de alzheimer.
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
TWI669119B (zh) 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
BR112019022906A2 (pt) * 2017-05-02 2020-05-26 Prothena Biosciences Limited Anticorpos que reconhecem tau
EP4233901A3 (en) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
WO2020069372A1 (en) * 2018-09-27 2020-04-02 Elstar Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
WO2020193644A1 (en) * 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF

Also Published As

Publication number Publication date
DOP2021000199A (es) 2022-07-15
US20220106387A1 (en) 2022-04-07
JP2025000645A (ja) 2025-01-07
MA55491A (fr) 2022-02-09
BR112021019107A2 (pt) 2021-11-30
PE20212266A1 (es) 2021-11-30
CL2022002670A1 (es) 2023-03-31
KR20210143858A (ko) 2021-11-29
CN120468431A (zh) 2025-08-12
CA3134785A1 (en) 2020-10-01
US11236155B2 (en) 2022-02-01
JP7617848B2 (ja) 2025-01-20
JOP20210265A1 (ar) 2023-01-30
EA202192606A1 (ru) 2022-01-24
CL2021002473A1 (es) 2022-04-22
EP3946603A1 (en) 2022-02-09
WO2020193644A1 (en) 2020-10-01
MX2021011715A (es) 2021-12-10
CN113891746A (zh) 2022-01-04
JP2022526528A (ja) 2022-05-25
IL286634A (en) 2021-10-31
CN113891746B (zh) 2025-05-06
US20250320286A1 (en) 2025-10-16
AU2020245031A1 (en) 2021-10-21
PH12021552334A1 (en) 2022-07-04
US20220177560A1 (en) 2022-06-09
CO2021014028A2 (es) 2021-10-29
CR20210492A (es) 2021-11-19
US20200308261A1 (en) 2020-10-01
SG11202110504XA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
ECSP21079184A (es) Anticuerpos contra amiloide-beta con piroglutamato y usos de estos
CL2020003096A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CL2019002922A1 (es) Anticuerpos anti-péptido beta amiloide n3pglu y sus usos.
CL2021002008A1 (es) Proteinas de unión de antígeno del receptor gamma anti-il2.
SV2008002511A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
MX2020011554A (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19).
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2019011520A (es) Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
ECSP066294A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
ECSP21046332A (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano y los métodos para su uso
MX2020006736A (es) Anticuerpos monoclonales y metodos para utilizar los mismos.
MX2025003354A (es) Anticuerpos que se unen a 5t4
CO2020014681A2 (es) Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
MX2021003119A (es) Anticuerpos anti-klrg1.
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
WO2021011673A3 (en) Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
MX2024007288A (es) Metodos de uso de un anticuerpo anti protofibrilla beta amiloide y anticuerpo anti tau.
EA202092123A1 (ru) Антитела против клаудина 18.2 и их применения
AR127898A1 (es) Anticuerpos terapéuticos que se unen al dominio serina·proteasa de masp-2 y usos de estos
CO2025013396A2 (es) Anticuerpos muc1 y cd16a y métodos de uso
CL2018002690A1 (es) Variantes del anticuerpo humanizado ban2401 que se une específicamente a protofibrillas con una vida media serica aumentada composiciones farmacéuticas y usos en el tratamiento del alzheimer y otras enfermedades neurodegenerativas (divisional de la solicitud n° 53-2017).
TH2101005857A (th) แอนติบอดีต่อไพโรกลูตาเมตแอมิลอยด์-เบตา และการใช้ของมัน